491 related articles for article (PubMed ID: 22968250)
1. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
Huang HT; Kang L; Huang PJ; Fu YC; Lin SY; Hsieh CH; Chen JC; Cheng YM; Chen CH
Menopause; 2012 Dec; 19(12):1360-3. PubMed ID: 22968250
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
Gomberg SJ; Wustrack RL; Napoli N; Arnaud CD; Black DM
J Clin Endocrinol Metab; 2011 Jun; 96(6):1627-32. PubMed ID: 21430030
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful?
Tarazona-Santabalbina FJ; Aguilella-Fernández L
Aging Clin Exp Res; 2013 Oct; 25(5):605-9. PubMed ID: 24026625
[TBL] [Abstract][Full Text] [Related]
4. Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment.
Yeh WL; Su CY; Chang CW; Chen CH; Fu TS; Chen LH; Lin TY
BMC Musculoskelet Disord; 2017 Dec; 18(1):527. PubMed ID: 29237448
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Schneider JP
Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
[TBL] [Abstract][Full Text] [Related]
6. A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
Cross MB; Nam D; van der Meulen MC; Bostrom MP
J Bone Joint Surg Br; 2012 Jul; 94(7):994-7. PubMed ID: 22733959
[TBL] [Abstract][Full Text] [Related]
7. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Chiu WY; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
[TBL] [Abstract][Full Text] [Related]
8. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Angthong C; Angthong W
J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
[TBL] [Abstract][Full Text] [Related]
9. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
11. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
Hsiao FY; Huang WF; Chen YM; Wen YW; Kao YH; Chen LK; Tsai YW
Clin Ther; 2011 Nov; 33(11):1659-67. PubMed ID: 22018450
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
13. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.
Carvalho NN; Voss LA; Almeida MO; Salgado CL; Bandeira F
J Clin Endocrinol Metab; 2011 Sep; 96(9):2675-80. PubMed ID: 21752890
[TBL] [Abstract][Full Text] [Related]
14. Atypical femoral fracture after long-term alendronate treatment: report of a case evidenced with magnetic resonance imaging.
Kao CM; Huang PJ; Chen CH; Chen SJ; Cheng YM
Kaohsiung J Med Sci; 2012 Oct; 28(10):555-8. PubMed ID: 23089322
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy.
Chiang CY; Zebaze RM; Ghasem-Zadeh A; Iuliano-Burns S; Hardidge A; Seeman E
Bone; 2013 Jan; 52(1):360-5. PubMed ID: 23072919
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
[TBL] [Abstract][Full Text] [Related]
17. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
18. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
19. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
Miller PD; McCarthy EF
Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
